Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: Long-term follow-up of RTOG study 73-03

Tupchong, Leslie; Phil, D.; Scott, Charles; Blitzer, Peter H.; Marcial, Víctor A.; Lowry, Louis D.; Jacobs, John R.; Stetz, JoAnn; Davis, Lawrence W.; Snow, James B.; Chandler, Richard B.; Krämer, Simon; Pajak, Thomas F.

doi:10.1016/0360-3016(91)90133-o

Cited by 223 publications

(103 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In total, 461 courses concomitant chemotherapy were applied. Median number of chemotherapy courses was 5 (range, [1][2][3][4][5][6][7][8]. Of the 100 patients, 59 received at least five courses, and I 20 23 49 21 44 19 II 33 24 20 1 13 12 III 23 16 3 0 0 2 IV 7 3 0 1 0 0 only 29 received at least six courses of chemotherapy.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Postoperative Radiochemotherapy With Weekly Cisplatin in Patients With Head and Neck Cancer Single-Institution Outcome Analysis

Pála

Odrážka²,

Holečková³

et al. 2012

neo

View full text Add to dashboard Cite

The objective of this study was to evaluate the feasibility, toxicity and efficacy of postoperative radiochemotherapy with weekly cisplatin in locoregionally advanced or high risk head and neck cancer in a single institutional setting.Patients with head and neck cancer of stage III/IV or patients with insufficient margins of resection were included in the study. Radiotherapy consisted of 70 Gy/ 7 weeks/ 35 fraction after R1/2 resection and 60-64 Gy/ 6-6,5 weeks/ 30-32 fraction after R0 resection, respectively. All patients received concurrent cisplatin 40 mg/m 2 weekly. Between 7/2002 and 12/2008, 100 consecutive patients [WHO ≤ 2, male to female ratio 84/16, median age 54 years] were treated. Tumors of the oropharynx were the most frequent (49%) and stage IV was predominant (86%). 96% patients received the full radiation treatment as planned, median total tumor dose was 66 Gy. Omission of weekly cisplatin had been occurring frequently, the most frequent reason for its early cessation were hematological toxicities (34%). Grade 3/4 mucosal toxicity developed in 32%. No death was observed during the treatment. The late toxicities were acceptable, predominantly subcutaneous fibrosis and xerostomia in most of the cases. We recorded six cases of osteonecrosis. Two and half year overall survival, locoregional control, time to progression and disease free survival were 64%, 88%, 79% and 59%, respectively.Postoperative radiochemotherapy with weekly cisplatin is toxic, but tolerable and highly effective in terms of locoregional control and survival. Multivariete analysis revealed that the only prognostic factor for survival was primary surgery at the University centre.

show abstract

Section: Resultsmentioning

confidence: 99%

“…However, despite postoperative radiotherapy, approximately 20-30% of patients still develop a typical locoregional recurrence within 2 years of treatment [7][8][9]. To improve results of a traditional approach, chemotherapy has been added to surgery and radiotherapy.…”

mentioning

confidence: 99%

Postoperative Radiochemotherapy With Weekly Cisplatin in Patients With Head and Neck Cancer Single-Institution Outcome Analysis

Pála

Odrážka²,

Holečková³

et al. 2012

neo

View full text Add to dashboard Cite

show abstract

“…La durée totale de la radiothérapie externe est un facteur déterminant pour le pronostic des cancers de la sphère ORL [30]. Au moins six études prospectives randomisées de phase III utilisant une radiothérapie externe exclusive ont été publiées [8][9][10][11]18,26].…”

Section: Discussionunclassified

“…La radiothérapie externe postopératoire à dose dite « conventionnelle » de 50-65 Gy est acceptée comme modalité thérapeutique « standard », sachant qu'elle réduit le taux des rechutes locorégionales de 50 % avec un taux final de contrôle locorégional de l'ordre de 70 à 80 % [23,30].…”

Section: Introductionunclassified

Radiothérapie externe accélérée postopératoire des carcinomes épidermoïdes localement évolués de la sphère ORL : étude prospective de phase II

Zouhair

Coucke

Azria

et al. 2003

Cancer/Radiothérapie

View full text Add to dashboard Cite

“…25,26 Patients with intermediate risk factors like pT3-T4, pN2-N3, and nodal disease in levels IV-V, PNI+ or LVI+ merit adjuvant radiotherapy. Based on two major phase III trials, Radiation Therapy Oncology Group (RTOG) 9501 and EORTC 22931 showed additional benefit with concurrent cisplatin chemotherapy in patients with high risk features like extra capsular spread or margin positive disease.…”

Section: Egfr Inhibitors In Adjuvant Settingmentioning

confidence: 99%

Current Status of Anti Epidermal Growth Factor Receptor Therapy in the Curative Treatment of Head and Neck Squamous Cell Carcinoma

Kainickal¹,

Aparna²,

Kumar³

et al. 2017

Cancer Stud Mol Med Open J

View full text Add to dashboard Cite

Citation ABSTRACTSquamous cell carcinoma of head and neck is the most common malignancy of the upper aero digestive tract in the world. In this article, we attempt to summarize the role of antiepidermal growth factor therapy (EGFR) in the treatment of locally advanced head and neck squamous cell carcinoma. Cetuximab plus radiotherapy is a reasonable alternative in patients who cannot tolerate standard concurrent chemoradiotherapy (CTRT). There is no benefit by adding targeted therapy in addition to standard CTRT. Trials evaluating the role of targeted agents in the adjuvant setting showed no benefit in patients with high risk features; in addition to standard post-operative CTRT. Role of adjuvant monoclonal antibody in patients with intermediate risk factors is being evaluated.

show abstract

Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: Long-term follow-up of RTOG study 73-03

Cited by 223 publications

References 26 publications

Postoperative Radiochemotherapy With Weekly Cisplatin in Patients With Head and Neck Cancer Single-Institution Outcome Analysis

Postoperative Radiochemotherapy With Weekly Cisplatin in Patients With Head and Neck Cancer Single-Institution Outcome Analysis

Radiothérapie externe accélérée postopératoire des carcinomes épidermoïdes localement évolués de la sphère ORL : étude prospective de phase II

Current Status of Anti Epidermal Growth Factor Receptor Therapy in the Curative Treatment of Head and Neck Squamous Cell Carcinoma

Contact Info

Product

Resources

About